🇺🇸 Polysporin Triple in United States

21 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 21

Most-reported reactions

1. Coagulation Time Prolonged — 3 reports (14.29%)
2. Drug Interaction — 3 reports (14.29%)
3. Off Label Use — 3 reports (14.29%)
4. Anxiety — 2 reports (9.52%)
5. Cough — 2 reports (9.52%)
6. Fistula — 2 reports (9.52%)
7. Nasopharyngitis — 2 reports (9.52%)
8. Urticaria — 2 reports (9.52%)
9. Abdominal Discomfort — 1 report (4.76%)
10. Abdominal Distension — 1 report (4.76%)

Source database →

Frequently asked questions

Is Polysporin Triple approved in United States?

Polysporin Triple does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Polysporin Triple in United States?

University Health Network, Toronto is the originator. The local marketing authorisation holder may differ — check the official source linked above.